免疫疗法
医学
CD28
单克隆抗体
抗原
癌症研究
免疫系统
免疫学
彭布罗利珠单抗
抗体
双特异性抗体
CD8型
作者
Janelle C. Waite,Bei Wang,Lauric Haber,Aynur Hermann,Erica Ullman,Xuan Ye,Drew Dudgeon,Rabih M. Slim,Dharani K. Ajithdoss,Stephen Godin,Ilyssa Ramos,Qi Wu,Erin M. Oswald,Patrick Poon,Jacquelynn Golubov,Devon Grote,Jennifer Stella,Arpita Pawashe,Jennifer Finney,Evan Herlihy
标识
DOI:10.1126/scitranslmed.aba2325
摘要
Monoclonal antibodies that block the programmed cell death 1 (PD-1) checkpoint have revolutionized cancer immunotherapy. However, many major tumor types remain unresponsive to anti-PD-1 therapy, and even among responsive tumor types, most of the patients do not develop durable antitumor immunity. It has been shown that bispecific antibodies activate T cells by cross-linking the TCR/CD3 complex with a tumor-specific antigen (TSA). The class of TSAxCD3 bispecific antibodies have generated exciting results in early clinical trials. We have recently described another class of "costimulatory bispecifics" that cross-link a TSA to CD28 (TSAxCD28) and cooperate with TSAxCD3 bispecifics. Here, we demonstrate that these TSAxCD28 bispecifics (one specific for prostate cancer and the other for epithelial tumors) can also synergize with the broader anti-PD-1 approach and endow responsiveness-as well as long-term immune memory-against tumors that otherwise do not respond to anti-PD-1 alone. Unlike CD28 superagonists, which broadly activate T cells and induce cytokine storm, TSAxCD28 bispecifics display little or no toxicity when used alone or in combination with a PD-1 blocker in genetically humanized immunocompetent mouse models or in primates and thus may provide a well-tolerated and "off the shelf" combination approach with PD-1 immunotherapy that can markedly enhance antitumor efficacy.
科研通智能强力驱动
Strongly Powered by AbleSci AI